CD36 and metabolic dysfunction-associated steatotic liver disease: A single administration of sgRubicon‐LNP reduced hepatic steatosis and lipid accumulation, regulated the glycerophospholipid metabolism pathway, and reduced CD36 expression, showcasing its potential to alleviate NAFLD.